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Vascular hyporesponsivenessNitric oxide (NO)producedby theNO synthase type 2 (NOS-2) is known tohave a prominent role in the course of
the inﬂammatory response but less is known concerning the role of NO derived from the constitutive NOS
isoforms. We have examined the role of NO derived from NOS-1 in the initiation of the systemic inﬂammatory
response using sepsis models. Injection of LPS in rats induced an early hypotension, NOS-2 expression, increased
lung myeloperoxidase activity and increased NO metabolite (NOx) levels in the skeletal muscle. Pre-treatment
with 7-nitroindazol (7-NI) prevented all these changes, but its administration after LPS injection was ineffective.
Septic (cecal ligation and puncture method, CLP) rats exhibited signs of organ failure, hyporesponsiveness to
vasoconstrictors and 75%mortality over 3 days after surgery. Pre-treatment with 7-NI prevented or signiﬁcantly
reduced these alterations. Injection of 7-NI after sepsis onsetwaswithout effect.Wild typemice injectedwith LPS
exhibited increased plasma NOx, NOS-2 and COX-2 expression and 80%mortality. NOS-1−/−mice injected with
LPS exhibited smaller increase inplasmaNOx,noNOS-2 andCOX-2expressionand reducedmortality. Injectionof
an NO donor in CLP rats pre-treatedwith 7-NI or in NOS-1−/−mice returned themortality rate to those of CLP in
rats and LPS inmice. Our results demonstrate thatNOS-1-derivedNOacts as a signaling element and it is essential
for the initiation of systemic inﬂammation as demonstrated by the reduction of the inﬂammatory response and
mortality by both pharmacological inhibition and genetic deletion of NOS-1.logy, Block “D”/CCB, Universi-
nopolis, SC, 88040-900, Brazil.
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In the early 1990s, a simple and general view for the biological role of
nitric oxide (NO) was established: low levels of NO synthesized by
constitutivenitric oxide synthases (NOS;NOS-1andNOS-3) are involved
in normal physiological events (Amezcua et al., 1998; Belvisi et al., 1991;
Greenberg et al., 1998), whereas high levels of NO produced by NOS-2
have a role primarily in pathological processes (Beishuizen et al., 1998;
Julou-Schaeffer et al., 1990; Stadler, et al., 2008). Although this rather
simplistic view is still accepted, it is clear thatNOplays diverse roles. This
is due to the wide distribution of NOS isoforms and the ability of NO to
interact with different targets (Bogdan, 2001). NO produced by the
constitutively expressed isoform NOS-3 (activated in response to aninﬂammatory stimulus) in the early stages of the immune/inﬂammatory
response (Bucci et al., 2005; Connelly et al., 2001) and sepsis (Connelly
et al., 2005; Vo et al., 2005) has an important regulatory role.
Sepsis is oftendeﬁned as a systemic inﬂammatory response coursing
in conjunction with an infection. Despite signiﬁcant advances in the
treatment of sepsis, the mortality rates remain unacceptably high
(Dombrovskiy et al., 2007). The abnormalities found in sepsis include
low blood pressure and biochemical signs of oxygen deﬁcit, accompa-
nied by vascular damage, hyporesponsiveness to vasoconstrictors, and
disseminated intravascular coagulation, all leading to multiple organ
dysfunction and death (Annane et al., 2005; Brandtzaeg, 1996).
NOS-2 remains as one of the focus of study in the relationship
between NO and sepsis (for review see Assreuy, 2006). However, in the
last decade some studies have showed the participation of NOS-3
(Connelly et al., 2005; Vo et al., 2005; Yamashita et al., 2000) and NOS-1
(Enkhbaatar et al., 2003, 2009; Gocan et al., 2000) in the pathogenesis of
the systemic inﬂammatory response. NOS-1 constitutes the predomi-
nant source of NO in neurons and synaptic spines, but it is found in
relevant amounts in the skeletal (Kobzik et al. 1994), cardiac (Xu et al.
1999) and smoothmuscles (Boulanger et al. 1998). In blood vessels, NO
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and Meissner, 2001).
In pathological conditions such as systemic inﬂammatory response,
NO produced by skeletal muscle NOS-1 affects vascular responsiveness
in septic animals (Gocan et al., 2000), and the inhibition of this enzyme
isoform by the selective inhibitor 7-nitroindazole (7-NI) attenuates
acute lung injury in a sheep model of sepsis (Enkhbaatar et al., 2003).
More recently, it has been suggested that NO produced by NOS-1 is
mainly involved in the early response to bacterial challenge (Lange et al.,
2010, 2011). Thus, taking into account that NOS-1 is constitutively
expressed in awide array of peripheral cells and tissues (Greenberg et al.,
1998;Qu et al., 1999), in thepresent reportwehave examined the role of
NO derived from NOS-1 in the initiation of the systemic inﬂammatory
response in endotoxemic and sepsis models.
2. Materials and methods
2.1. Animals
Wistar rats (200–250 g) were from the University colony. Mice
(20–25 g) homozygous for targeted disruption of the NOS-1 gene
(B6,129-NOS-1tm1Plh, nNOS−/−; Huang et al., 1993) and C57BL/6 mice
were purchased for The Jackson Laboratory, Bar Harbor, Maine, USA.
Animals used in this study were housed in a temperature- (23±2 °C)
and light- (12 h light/dark cycle) controlled room, with free access to
food and water. All procedures were performed in accordance with
the National Institutes of Health Guidelines and approved by the
Institutional Animal Care and Use Committee of Universidade Federal
de Santa Catarina. Anesthetic procedure was always carried out with
ketamine 100 mg/kg i.p., Parke-Davis, São Paulo, SP, Brazil and
xylazine 20 mg/kg i.p., Bayer, São Paulo, SP, Brazil.
2.2. Endotoxin treatment
Rats and mice were injected with endotoxin (LPS; Escherichia coli
lipopolysaccharide 0111:B4; Sigma, St. Louis, MO, USA), dissolved in
sterile, pyrogen-free saline. Experiments were performed at two
different times after LPS injection. First, a group of anesthetized rats
was injected with 10 mg/kg LPS i.p. and blood pressure was measured
continuously until 120 min after endotoxin injection. Animals were
then immediately sacriﬁced by exsanguination through the left
carotid artery. Blood, lung and skeletal muscle (quadriceps) were
obtained for measurement of NOx content (see below). A second
group of rats was injected with LPS i.p. and 8 h later was anesthetized
as above and sacriﬁced by exsanguination. Blood was obtained for
measurement of plasma NOx, and the lung was harvested for NOS
activity, Western blot analysis, and myeloperoxidase (MPO) activity.
Tissueswere kept at−80 °C until the assay, for nomore than amonth.
Mice were injected with 20 mg/kg LPS i.p. and tissues harvested 8 h
after treatment for Western blotting analysis and NOxmeasurements.
For survival curves, mice were injected with LPS (20 mg/kg, i.p.) and
mortality was recorded daily at noon for up to 3 days.
2.3. Cecal ligation and puncture
Sepsiswas inducedby cecal ligation andpuncture (CLP) as previously
described (Wichtermanet al., 1980)withmodiﬁcations(Fernandes et al.,
2009). Brieﬂy, rats were anesthetized and after laparotomy, the cecum
was ligated distal to the ileocecal valve, punctured 20 times with a 21-
gage needle, and a small amount of cecal content was squeezed through
thepunctures. The cecumwasplacedback into the abdominal cavity, and
the wound was closed with two layers of sutures. All animals received
saline (20 ml/kg, s.c) after the surgery. Sham-operated ratswere handled
in the same manner, except that the cecum was neither ligated nor
punctured. Thirty-six hours later, septic rats were instrumented for
blood pressure measurement. At the end of the experiment, blood wasobtained for total leukocyte counting andmeasurement of plasmaNOx,
and tissue was harvested from the lungs for NOS and MPO activity
assays.Mortalitywas recordeddaily at noon for up to oneweek after the
surgical procedure.
2.4. Blood pressure measurement
Rats were anesthetized and body temperature was maintained at
37 °C bymeans of a heating pad. The carotid artery was cannulated for
monitoring arterial pressure and the femoral vein for administration
of phenylephrine. Increasing doses of phenylephrine (3, 10 and
30 nmol/kg) were injected in 0.1-ml boluses and the cannula ﬂushed
with saline. Injections weremade only after the effect of the preceding
dose has completely waned and the blood pressure had returned to
basal levels. For experiments performed with endotoxin, rats were
prepared for blood pressure measurement and 30 min later LPS was
injected. For experiments performed with the CLP model, rats were
prepared for blood pressure measurement 36 h after surgery.
2.5. Measurement of nitrite and nitrate
Plasma and tissue NOx contents were determined by ﬁrst reducing
nitrate using nitrate reductase expressed in E. coli grown anaerobically
(Granger et al., 1990). Samples were collected at the times indicated in
the ﬁgure legends. Tissues were homogenized in cold buffer (320 mM
sucrose, 50 mMTris–HCl, 1 mMdithiothreitol, 10 μg/ml soybean trypsin
inhibitor, 10 mg/ml phenylmethylsulphonyl ﬂuoride, pH 7.2). After
centrifugation (30,000×g, 30 min, 4 °C), the supernatantswere adjusted
to a protein content of 30 mg/ml and kept in ice until analysis. Brieﬂy,
samples were deproteinized with zinc sulfate (10% w/v stock; added
1/10 of sample volume) and to 100 μl of deproteinized samples were
added 20 μl 0.5 MNaH2PO4 pH 7.2; 20 μl 2.4 M ammonium formate; pH
7.2, and 10 μl anaerobically-grown live E. coli, 300 mg/ml, followed by
incubation for 3 h at 37 °C. After incubation, samples were centrifuged
for bacteria removal, then100 μl of the clear supernatantwasmixedwith
100 μl of Griess reagent (1% sulfanilamide in 10% phosphoric acid/0.1%
naphtylethylenediamine inMilli-Qwater) in a 96-well plate, followedby
reading at 540 nm in a plate reader (Ultra Microplate Reader 808, Bio-
Tek Instruments, Inc., USA). Standard curves of nitrite and nitrate (0 to
150 μM) were run simultaneously. As under these conditions nitrate
conversion was always greater than 90%, no corrections were made.
Values are expressed as μMNOx.
2.6. NOS activity assay
NOS activity was assayed by measuring the conversion of 3H-L-
arginine to 3H-L-citrulline as previously described (Duma et al., 2004),
with minor modiﬁcations (1 mg of protein and 500 μl of resin). Tissues
were homogenized in cold buffer (320 mM sucrose, 50 mM Tris–HCl,
2 mM dithiothreitol, 10 μg/ml soybean trypsin inhibitor, 10 mg/ml
phenylmethylsulphonyl ﬂuoride, 20 mM sodium molybdate, 10%
glycerol, pH 7.2). After centrifugation (30,000×g, 30 min, 4 °C) the
supernatant was used for the NOS assay. Brieﬂy, 50 μl of tissue
homogenate (~1 mg tissue protein) was incubated with 50 μl of a
cocktail containing 3H-L-arginine and the required substrates and
cofactors (35 nM 3H-L-arginine, 50 mM KH2PO4; 1.2 mM MgCl2;
0.25 mM CaCl2; 60 mM L-valine; 1.2 mM L-citrulline and 1 mM
dithiothreitol, pH 7.2) for 1 h at room temperature. The reaction was
stopped and free 3H-L-arginine was separated from 3H-L-citrulline by
the addition of 500 μl of a resin (Dowex AG-50x8, Na+ form, 1:1 in
water, pH 6.7) that binds to 3H-L-arginine. After centrifugation
(10,000×g, 3 min, room temperature), the supernatant (100 μl) was
mixedwith1 mlof scintillationﬂuid. 3H-L-citrullinewas thenquantiﬁed
by liquid scintillation counting. For the quantiﬁcation of calcium-
independent NOS (NOS-2) activity, EGTA (1 mM) was added to the
assay buffer. For every sample a blankwas run by adding EGTA andN-5-
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assay buffer. Results are expressed as pmol citrulline/min/mg protein.
2.7. Western blot analysis
Lungs, quadriceps and cerebellum from control rats and lungs from
control and treated mice were homogenized in ice-cold buffer (in mM:
50 HEPES, 1 MgCl2, 10 EDTA, and 1% Triton X-100, pH 6.4, containing
1 μg/ml each of aprotinin, leupeptin, soy bean trypsin inhibitor, and
1 mM phenylmethylsulphonyl ﬂuoride). After centrifugation
(10,000×g, 30 min), supernatant protein content was estimated by
absorbance at 280 nm. Protein samples (100 μg/lane)were subjected to
gel electrophoresis (SDS/PAGE, 8% gel). After electrophoresis, the
proteins were transferred onto PVDF membrane (1 h; 15 V) in Tris–
glycine buffer (48 mM Tris–HCl and 39 mM glycine). Membranes were
blocked in T-PBS (137 mMNaCl, 2.7 mMKCl, 1.5 mMKH2PO4, 10.8 mM
Na2HPO4 and 0.05% Tween-20, pH 7.4) containing 5% nonfat milk for
16 h at 4 °C. Membranes were washed with T-PBS at 5 minute intervals
for 15 min and incubated with NOS-1, NOS-2, or COX-2 antibodies
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 4 h at room
temperature. Following washing (5 minute intervals for 15 min),
membranes were incubated with horseradish peroxidase-anti-rabbit
IgG (1:1000) for 1 h at room temperature. The immunoreactive bands
were visualized by using an enhanced chemiluminescence system (ECL,
Amersham Pharmacia). The bands were quantiﬁed by densitometry
using Scion Image software (Scion Co., Frederick, MD, USA).
2.8. Myeloperoxidase measurement
Rats were sacriﬁced by exsanguination. Lungs were homogenized in
hexadecyltrimetylammonium bromide buffer (HTAB, 0.5% in 50 mM
sodiumphosphate buffer, pH 5.4) by using anUltra-Turraxhomogenizer0 30
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Fig. 1. Effect of 7-nitroindazole on the blood pressure and plasma nitrite/nitrate (NOx) levels after l
and 1 h later, instrumented for blood pressure measurement. Following a stabilization period,
pressure immediately before LPS injection (97.3±8.4 mmHg) and the pressure at the evaluation
analysis was performed by ANOVA followed by t-test subjected to the Dunnett's correction. * Me
pressure assay, rats were sacriﬁced and NOx levels were evaluated in the plasma (Panel B), and in
analysis was performed by ANOVA followed by t-test subjected to the Bonferroni's correction; *P(20 s at maximum speed). After centrifugation of homogenates
(10,000×g, 4 °C for 15 min) supernatant fractions (25 μl, ~ 0.02 mg
protein) were assayed for MPO activity. The enzymatic reaction was
developed in the presence of tetramethylbenzidine (1.6 mM in distilled
water) and hydrogen peroxide (0.5 mM in phosphate buffer, pH 5.4) for
5 min at 37 °C. Following incubation, the reaction was stopped with
H2SO4 1 N. Absorbance was measured at 450 nm in a microplate reader
(Ultra Microplate Reader 808, Bio-Tek Instruments, Inc., USA). MPO
activity was expressed as optical density units at 450 nm/mg protein.
2.9. Serum measurements
Rats subjected to the CLP procedure were anesthetized and sacriﬁced
36 h after surgery by exsanguination. Blood was obtained by cardiac
punctureand serumlevels of ureanitrogenandcreatinineweremeasured
with commercially available clinical assay kits (Gold Analisa Diagnostica,
Minas Gerais, MG, Brazil).
2.10. Leukocyte count
Leukocyte counts were performed on blood samples. Total
leukocyte counts were made in a Neubauer chamber and were
expressed as cells/mm3×103.
2.11. Data analysis
All statistical analysis was performed using GraphPad Prism
(GraphPad Software Inc., San Diego, CA). Data are expressed as mean±
S.E.M. (n=6 to 8 animals for each group). Statistical signiﬁcance was
analyzed by analysis of variance (ANOVA) followed by Bonferroni's t-test
formultiple comparisons or by Dunnett's correction to compare temporal
changes in mean arterial pressure in normal and endotoxemic animals.60 90 120
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points ( MAP inmmHg), and represents themean±S.E.M. of 4–6 rats per group. Statistical
ans statistically signiﬁcant difference compared to zero time (Pb0.05). At the end of blood
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Fig. 2.Calcium-dependentNOSactivity and levels ofNOS-1protein in lungs, quadricepsand
cerebellum homogenates from normal rats. Samples were assayed for calcium-dependent
NOS activity (Panel A), submitted to electrophoresis, transferred to blotting paper and
probed with anti-NOS-1 antibody (representative experiment shown in Panel C). Blots
were digitalized for the densitometry (Panel B). Data representmean±S.E.M. of 3 samples
and where there are no error bars, they were covered by the bar line.
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survival analysis. A P value less than 0.05 was considered signiﬁcant.
3. Results
3.1. NOS inhibition prevents LPS-induced early and transient hypotension
LPS (10 mg/kg, i.p.) injection led to a transient decrease in the mean
arterial pressure (MAP; ~ 25 mmHg), which peaked 75 min after LPS
injection and began to return to the normal level thereafter (Fig. 1A).
Previous studies have demonstrated that following the initial recovery,
MAP started to decline again until death (Connelly et al., 2005). The
biphasic effect on MAP caused by LPS was also observed in animals
submitted to cecal ligation andpuncture (CLP) surgery (datanot shown).
To evaluate the potential role of NOS-1 in this early and transient
hypotension, endotoxemic rats were pre-treated with 7-nitroindazol
(7-NI) 1 h before LPS injection. The NOS inhibitor (Fig. 1A) blocked the
initial LPS hypotensive effect and MAP remained unchanged until the
end of the experimental period (120 min). Importantly, contrary to
other NOS inhibitors (such as L-NMMA and L-NAME; Alderton et al.,
2001), 7-NI did not affect the blood pressure of normal animals,
indicating a lack of effect on the endothelial NOS isoform (NOS-3). As
seen in Fig. 1C, LPS injection caused a clear increase in nitrite+nitrate
(NOx) content in skeletalmuscle (quadriceps) homogenates,whichwas
blocked by the pre-treatment with 7-NI. Plasma and lung homogenate
NOx content did not change signiﬁcantly (Fig. 1C and D, respectively).
The skeletalmuscle as a source of NOwas conﬁrmed by theﬁndings of a
calcium-dependent NOS activity in the muscle but not in the lung(Fig. 2A) aswell as immunoreactivity forNOS-1 in themuscle, but not in
the lung (Fig. 2B). In both cases cerebellumhomogenateswere used as a
positive control because of its high content of NOS-1 (Huang et al.,
1993).
3.2. NOS-1 inhibition affects parameters of LPS-induced systemic inﬂam-
matory response
Injection of LPS induced the activity of a Ca2+-independent NOS
(presumably to be NOS-2, the inducible isoform) in the lung and
spleen of rats (Fig. 3A and B, respectively). When administered 1 h
before LPS, 7-NI prevented the appearance of NOS-2-like activity
induced by LPS in both organs. In contrast, when the inhibitor was
administered 4 h after LPS, it completely failed to modify the NOS-2-
like expression proﬁle. The same pattern was observed for two other
parameters, NOx plasma levels and lung MPO activity (Fig. 3C and D,
respectively).
3.3. LPS-induced inﬂammatory response in NOS-1−/− mice
In order to further conﬁrm the critical role of NOS-1 in the initiation
of the inﬂammatory response, LPS-induced inﬂammationwasevaluated
in NOS-1 knockoutmice. As shown in Fig. 4A, LPS failed to induce NOS-2
and COX-2 expression in the lungs of NOS-1 knockoutmice. In addition,
the level of NOS-2 in the skeletal muscle of NOS-1 knockout mice was
considerably lower than in wild type controls (data not shown).
Accordingly, there was a signiﬁcant reduction in the accumulation of
plasma NOx in LPS treated knockout mice (Fig. 4B). To conﬁrm that
deletion of NOS-1 attenuates the systemic inﬂammatory response,
survival studieswereperformedusing a lethal dose of LPS (30 mg/kg). It
is shown in Fig. 5 that injection of a lethal dose of LPS caused a 75%
mortality of wild type mice within 36 h. The LPS-induced mortality in
the NOS-1 knockout mice was reduced to 35%. However, when NOS-1
knockout mice were treated with the NO donor S-nitroso-acetyl-DL-
penicillamine (SNAP, 1.4 μmol/kg, i.p.) 75 min after LPS (tomimic NOS-
1-derived NO pulse at the same time), the mortality was raised to 90%
within 36 h drawing a clear parallel between the initial early pulse of
NOS-1-derived NO and the intensity of the inﬂammatory response.
3.4. NOS-1 inhibition prevents vascular hyporesponsiveness and reduces
mortality in the CLP model
Although LPS injection is an adequate model to evaluate the
inﬂammatory consequences of endotoxemia, CLP is regarded as being
a more realistic model when sepsis/septic shock is concerned. Table 1
shows the parameters of systemic inﬂammatory reaction 36 h after
CLP. Bodyweight reduction, leukopenia and increased plasma NOx, all
caused by CLP, were prevented or reduced (lung MPO activity) in
animals treated with a single dose of 7-NI administered 1 h before
surgery. In sharp contrast, 7-NI injected after the surgery was
ineffective in changing the course of sepsis. CLP surgery also induced
hypotension and hyporesponsiveness to phenylephrine (Table 1 and
Fig. 6A). Again, pre-treatment with 7-NI completely prevented these
changes, whereas the injection of the NOS inhibitor after CLP failed in
modifying any parameter. Fig. 6B shows the rate of mortality of CLP
rats. Pretreatment with 7-NI one hour before surgery delayed death.
In agreement with survival studies in NOS-1 knockout mice (Fig. 4),
SNAP given to 7-NI pre-treated rats abolished the protection afforded
by NOS inhibition with 7-NI.
4. Discussion
During the past two decades, NO has been recognized as being
involved in the pathogenesis and control of infectious diseases, tumors,
autoimmune processes and chronic degenerative disorders (reviewed
inBogdan, 2001). Studies ofNOand inﬂammationhave focusedmainlyon
01
2
3
* *
A
0
100
200
300
400
500
*
*
C
*#
N
O
x 
(µ
mo
l/L
)
0
1
2
3
* *
B
VEH 7NI LPS 7NI LPS
                                       +           +
                                     LPS       7NI
Ca
2+
-
in
de
pe
nd
en
t N
O
S 
ac
tiv
ity
(p
mo
l c
itr
ull
ine
/m
in/
mg
 pr
ot
ein
)
Ca
2+
-
in
de
pe
nd
en
t N
O
S 
ac
tiv
ity
(p
mo
l c
itr
ull
ine
/m
in/
mg
 pr
ot
ein
)
0
10
20
30
40
*
*
VEH 7NI LPS 7NI LPS
                                       +            +
                                     LPS       7NI
D
M
PO
 a
ct
iv
ity
(u
nit
s 4
50
 nm
/m
g p
ro
tei
n)
Fig. 3. Consequences of NOS-1 inhibition on LPS-induced increase in Ca2+-independent NOS activity, plasma NOx andmyeloperoxidase activity. Rats were given LPS or vehicle (VEH)
and 8 h later were sacriﬁced for lung, spleen and blood harvesting and assay. In the group 7-NI+LPS, 7-nitroindazole (7-NI) was administered 1 h before LPS injection. In the group
LPS+7-NI, the inhibitor was administered 4 h after LPS injection. Panel A: Ca2+-independent NOS activity in the lung; Panel B: Ca2+-independent NOS activity in the spleen; Panel C:
plasma NOx levels and Panel D: lung MPO activity. Data represent mean±S.E.M. of 4–6 animals per group. *Pb0.05 compared to vehicle group and #Pb0.05 compared with LPS
group. ANOVA followed by t-test subjected to the Bonferroni's correction.
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produced by NOS-3 (Bucci et al., 2005; Cirino et al., 2003; Connelly et al.,
2001; Vo et al., 2005). Although it has been shown that lack of NOS-3 has
no effect in LPS-induced mortality (Shesely et al., 1996), some reports
suggest that NOS-3-derived NO may be protective in endotoxemic and
septic shock. For instance, NOS-3 protects against systemic inﬂammation
and hypotension in mice injected with LPS (Connelly et al., 2005),
overexpression of NOS-3 in the endothelium results in resistance to LPS-
induced death (Yamashita et al., 2000) and NOS-3 protects against
systemic inﬂammation and myocardial dysfunction in murine poly-
microbial sepsis (Bougaki et al., 2010; Ichinose et al., 2007). These results
suggest that NOS-3-derived NO is protective against the deleterious
effects of LPS and sepsis.
Notwithstanding a relevant role for NOS-3-derived NO in sepsis, the
main ﬁnding of the present report is to provide evidence that NOS-1-
derived NO not only act as an effector (as in neurotransmission, for
example) but also plays a critical role as a signaling element in the
induction and intensity of the systemic inﬂammatory response. By using
both pharmacological and genetic approaches in twomodels of systemic
inﬂammatory responses in two different species, our data clearly
demonstrated that a pulse of NO derived from NOS-1 at the early stages
after LPS or CLP is essential for the onset of the systemic inﬂammatory
response andcritical inmodulating its intensity. Indeed, by inhibiting this
NO pulse we were able to ameliorate hemodynamic and inﬂammatory
parameters that translated into increased survival after LPS or CLP.
Importantly, a robust inﬂammatory response was induced in NOS-1
knockout animals by combining LPS and an exogenous source of NO
injected 75 min after the endotoxin, unequivocally establishing the pulse
of NO as a critical modulator of the inﬂammatory response. Finally, ourresults are suggestive that at least one source of the “NO pulse signaling”
seems to be the NOS-1, most likely the enzyme present in the skeletal
muscle.
The injection of LPS led to a biphasic effect on rat blood pressure:
ﬁrst, an acute hypotensive effect that is rapid in onset and short-lived,
followed by a delayed hypotension that takes place 6–8 h after LPS and
exhibits a good correlation with the time course of NOS-2 expression
(Connelly et al., 2005; Rees et al., 1998). It has been demonstrated that
the ﬁrst drop in MAP induced by LPS is linked to NOS-3 activation
(Connelly et al., 2005). Here we show that NOS-1-derived NO is also
contributing/mediating to the initial hypotension since the pre-
treatment with 7-NI, a NOS-1 inhibitor, completely blunted the LPS
early hypotensive effect. Considering that i) 2 h after LPS NOS-2 has not
yet been expressed; ii) 7-NI did not change the blood pressure and
therefore is not interferingwithNOS-3 activity (Moore et al., 1993); and
iii) NOS-1 knockout animals did not mount a proper inﬂammatory
response as thewild typemice, it is reasonable to attribute the release of
this early hypotensive NO pulse to NOS-1 activity.
NOS-1 has been detected in skeletal muscle of rat, mouse and
human by immunological, histochemical, and cellular fractionation
methods (reviewed in Alderton et al., 2001). Our results conﬁrm the
existence of NOS-1 in the rat skeletal muscle, by both immunoblotting
and enzymatic activity. Importantly, although the NOS-1 content in
the skeletal muscle is lower than those found in nervous tissues, the
large mass of skeletal muscle, comprising up to 40% of the dry body
weight, suggests that NOS-1 may be an important source of NO and a
major signal effector enzyme. The increased NOx content in the
skeletal muscle and the drop in the blood pressure induced by LPS
were abrogated by 7-NI, suggesting that NOS-1-derived NO produced
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Fig. 4. Expression of NOS-2 and COX-2 and NOx levels induced by LPS in NOS-1
knockout mice. Panel A: LPS (20 mg/kg i.p.) or saline was injected and 8 h later, lung
was electrophoresed and immunoblotted for NOS-2 and COX-2. Actin served as a
loading control. Samples in each lane were obtained from different mice. Panel B:
Plasma was harvested from the same mice and assayed for NOx. *Pb0.05 compared to
control group (saline) and #Pb0.05 compared with wild-type mice injected with LPS.
ANOVA followed by Bonferroni's correction.
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Fig. 5. LPS-induced mortality in NOS-1 knockout mice and the effect of NO replenishment.
LPS (20 mg/kg, i.p.) was injected and survival was monitored twice a day for 72 h. SNAP
(S-nitroso-D,L-acetylpenicillamine; 1.4 μmol/kg, i.p.) was injected 75 min after LPS. Experi-
ments were performed with at least 12 animals per group.
290 D. Duma et al. / European Journal of Pharmacology 668 (2011) 285–292in the skeletal musclemay be, at least in part, related to the immediate
and transient decrease in MAP. Also relevant was the ﬁnding that
NOS-1-derived NO has a crucial role in potentiating systemic
inﬂammation. For instance, pharmacological inhibition of NOS-1 by
7-NI pretreatment has a profound impact on the deleterious effect of
LPS or CLP. Protective effects afforded by the NOS-1 inhibitor 7-NI were
only seen when the drug was injected prior to LPS and completely lost
when the inhibitor was injected after the initial hypotensive phase.
Taken together, these ﬁndings demonstrate that a transient focal
activation of NOS-1 serves as trigger for the activation of downstream
inﬂammatory effectors. It is important to note that absence/reduction of
the expression and product of inﬂammatory proteins (NOS-2 and NO)
induced by a systemic inﬂammatory insult (LPS) in animals pretreated
with NOS-1 inhibitor was also found in a genetic model of NOS-1
inhibition, namely the NOS-1 knockout mouse. These data is consistent
to reports showing that i) NO produced by NOS-1 affects vascular
responsiveness in septic animals (Gocan et al., 2000; Lidington et al.,
2007); ii) 7-NI attenuated acute lung injury in an ovine model of sepsis
(Enkhbaatar et al., 2003); and iii) the reduction in arteriolar conducted
vasoconstriction in septic mouse cremastermuscle ismediated byNOS-
1-derived NO (McKinnon et al., 2005). Additionally, recent reports have
shown that the early inhibition of NOS-1 in a murine model of
pulmonary sepsis was associated with reduced content of lung NOx
and liver injury (Lange et al., 2010, 2011).Contrary to our ﬁndings, others have shown that the pharmaco-
logical inhibition of NOS-1 increases the expression of inﬂammatory
proteins including NOS-2 (Cui et al., 2007; Qu et al., 2001). However,
two substantial differences in the experimental protocols may explain
these opposite results. First, a chronic treatment with the NOS-1
inhibitor (Qu et al., 2001) while ours consisted of a single dose. Second
and perhapsmore relevant, the dose of 7-NI was 250- (Qu et al., 2001)
to 400-fold (Cui et al., 2007) higher than the dose used in the present
work.
Closer inspection of results shown in Fig. 4 indicates that COX-2
expression is substantially increased after LPS. COX-2 is an inﬂammatory
protein whose levels correlate with the severity of the inﬂammatory
response (Kniss, 1999). Inhibition of COX-2 results in improvement in
early survival in murine endotoxemia (Reddy et al., 2001), ameliorated
cytokine and cellular immunologic imbalances anddecreased liver injury
(Li et al., 2009). COX-2 deﬁcient mice are resistant to the detrimental
consequences of endotoxemia (Ejima et al., 2003). Our results show that
LPS failed to induce COX-2 expression in animals lacking NOS-1 gene,
most likely due to the absence of the NOS-1-derived NO pulse. Although
we did not explore it further, it is conceivable that at least part of the
beneﬁcial effect of NOS-1 deﬁciency may be attributable to the lack of
LPS-induced COX-2 expression.
Sepsis is known to have both inﬂammatory and cardiovascular
components. The vascular dysfunction is evidenced by hypotension and
loss in vascular response to vasoconstrictors (Fernandes et al., 2009). A
drop in leukocyte number evidences systemic inﬂammatory response
during sepsis that is, at least in part, due neutrophil migration to the
infectious focus and to other organs like the lungs (Alves-Filho et al.,
2008). In both LPS and CLP models, pre-treatment with 7-NI prevented
the onset of both inﬂammation and the onset of the loss in the vascular
Table 1
Effect of NOS-1 inhibitor injected 1 h before (7-NI+CLP group) or 6 h after cecal ligation and puncture surgery (CLP+7-NI group) on several parameters of rats 36 h after CLP surgery.
Parametera Experimental group
Sham 7-NIb CLP 7-NI+CLP CLP+7-NI
Body weight reduction (%) 2.3±0.6 3.1±0.6 12.4±0.7c 4.3±0.8 13.6±1.0c
Leukocyte count (cells/mm3×103) 38.8±4.2 40.7±1.5 10.2±1.8c 28.2±8.7 13.2±0.9c
MPO activity (450 nm OD/mg protein) 49.4±4.2 63.8±3.0 158±14c 103±14c 145±21c
Plasma NOx (μmol/L) 17.4±1.0 22.8±1.9 48.6±3.7c 27.6±2.1 55.3±5.7c
Urea (mg/dL) 18.5±0.6 26.4±1.8 51.1±2.1c 27.9±2.4 45.7±2.8c
Creatinine (mg/dL) 2.3±0.7 4.7±0.9 64.5±13c 15.0±6.8 86.3±16.3c
Mean arterial pressure (mm Hg) 98.0±3.8 105.3±12 61.9±2.5c 85.5±3.1 73.0±3.2c
a Data are expressed as mean±S.E.M. of 6–8 animals per group.
b Sham animals that received 7-NI 1 h before or 6 h after CLP surgery are presented as one group.
c Pb0.05 compared to sham-operated group. ANOVA followed by Bonferroni's correction.
291D. Duma et al. / European Journal of Pharmacology 668 (2011) 285–292response to phenylephrine. Similarly, changes in several inﬂammatory,
cardiovascular and biochemical parameters indicative of end-organ
damage induced by CLPwere also prevented by the pre-treatmentwith
7-NI.WhenNOS-1 activity was inhibited 75–90 min after stimulus (and
presumably after the release of the initial “NO signaling pulse”), the
course of the inﬂammatory/cardiovascular reaction proceeded without
modiﬁcation. The course of events leading to organ failure and death
was so importantly modiﬁed by the absence of NOS-1-derived NO that
the mortality of NOS-1 knockout mice after a lethal dose of LPS was
reduced by 50%. NOS-1 inhibition by the pre-treatmentwith 7-NI in rats
also substantially reduced the mortality. These results provided0
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Fig. 6.NOS-1 inhibitiononvascular responseand survivalof rats submitted to cecal ligation
and puncture. Panel A, rats were injected with 7-NI 1 h before (7-NI+CLP group) or 6 h
after cecal ligation and puncture surgery (CLP+7-NI group). Third-six hours after surgery,
rats were prepared for blood pressure measurement and the vasoconstrictive effect of
phenylephrinewas evaluated. *Pb0.05 compared to sham-operated rats;ANOVA followed
by Bonferroni's correction. Panel B, groups 7-NI+CLP and CLP+7-NI as in Panel A. Part of
the group 7-NI+CLP animals was injected with S-nitroso-D,L-acetylpenicillamine (SNAP,
1.4 μmol/kg, i.p.) 2 h after CLP (7-NI+CLP+SNAPgroup). In Panel B, the group 7-NI+CLP
was statistically different from CLP group (Pb0.05) using the log-rank test (6–8 rats per
group).compelling strength to our hypothesis that a short initial pulse of NOS-
1-derived NO seems to be critical for the development of systemic
inﬂammation and that the suppression of NOS-1 activity at the early
stages of sepsis may be of pharmacological interest.
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